Long after the blockbuster shoutouts faded to a whisper, TherapeuticsMD gets an M&A deal - Endpoints News

Long after TherapeuticsMD’s boasts of blockbuster aspirations in the women’s health field had melted away to a revenue stream counted in droplets, the micro biotech player is being snapped up by a private equity group in an M&A deal valued at $177 million. Th…

Count GSK in for the pneumococcal vaccine race. The British pharma is wagering $2.1 billion in cash — plus up to $1.2 billion in milestones — to buy out Affinivax and its 24-valent pneumococcal vacc… [+560 chars]

full article...